News Immatics Announces Third Quarter 2022 Financial Results and Business Update by trophic 17 November, 2022
News Immatics Announces $110 Million Underwritten Offering of Ordinary Shares by trophic 10 October, 2022
News Immatics Reports Interim Clinical Data Update on ACTengine® IMA203 TCR-T Monotherapy Targeting PRAME by trophic 10 October, 2022
